Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03006172 | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | active not recruiting | Phase 1 | 200 | Genentech, Inc.INDUSTRY | 5 | Sep 8, 2026 | clinicaltrials |
| NCT03430492 | Sweden Cancerome Analysis Network - Breast (SCAN-B) Coupled to Psychological Resilience | active not recruiting | — | 985 | Lund UniversityOTHER | 1 | Sep 8, 2026 |
| clinicaltrials |
| NCT03939897 | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02208375 | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | active not recruiting | Phase 1 | 159 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | active not recruiting | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06112613 | Mobile Health for Adherence in Breast Cancer Patients | active not recruiting | N/A | 390 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 4, 2026 | clinicaltrials |
| NCT04724499 | Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy(CLARITY) | active not recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04873362 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy(Astefania) | active not recruiting | Phase 3 | 1,188 | Hoffmann-La RocheINDUSTRY | 32 | Sep 3, 2026 | clinicaltrials |
| NCT05025020 | Use of an Interactive 3D Tool During Consultation for Breast Reconstruction Surgery | active not recruiting | N/A | 88 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06055881 | Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy(BOSS) | active not recruiting | N/A | 45 | Mayo ClinicOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06813053 | A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer | active not recruiting | N/A | 60 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02750826 | Breast Cancer WEight Loss Study (BWEL Study) | active not recruiting | Phase 3 | 3,177 | Alliance for Clinical Trials in OncologyOTHER | 4 | Sep 2, 2026 | clinicaltrials |
| NCT03270072 | The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients | active not recruiting | — | 100 | Massachusetts General HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03317405 | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | active not recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03946202 | KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer | active not recruiting | Phase 2 | 184 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT04540692 | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer(NEOSAMBA) | active not recruiting | Phase 3 | 446 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05548127 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | active not recruiting | Phase 1 / Phase 2 | 37 | PfizerINDUSTRY | 4 | Sep 2, 2026 | clinicaltrials |
| NCT02301767 | MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study | active not recruiting | — | 2,187 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03401385 | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | active not recruiting | Phase 1 | 890 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT06399276 | 4:3 Intermittent Fasting Intervention in Adults With Breast Cancer and Overweight or Obesity | active not recruiting | N/A | 36 | University of Colorado, DenverOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07798492 | Effects of Supervised Aerobic Exercise on Biomarkers, Physical Function, and Quality of Life in Breast Cancer Survivors | active not recruiting | N/A | 20 | Gazi UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT01901094 | Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy | active not recruiting | Phase 3 | 2,012 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 31, 2026 | clinicaltrials |
| NCT02954874 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | active not recruiting | Phase 3 | 1,195 | National Cancer Institute (NCI)NIH | 3 | Aug 31, 2026 | clinicaltrials |
| NCT02955394 | Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer | active not recruiting | Phase 2 | 61 | University of Colorado, DenverOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05460273 | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | active not recruiting | Phase 1 / Phase 2 | 119 | AstraZenecaINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT00070564 | S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer | active not recruiting | Phase 3 | 3,294 | SWOG Cancer Research NetworkNETWORK | 3 | Aug 28, 2026 | clinicaltrials |
| NCT00433511 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | active not recruiting | Phase 3 | 4,994 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | active not recruiting | Phase 3 | 5,018 | National Cancer Institute (NCI)NIH | 10 | Aug 28, 2026 | clinicaltrials |
| NCT02311933 | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | active not recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02849496 | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer | active not recruiting | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04427293 | Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 | 12 | University of Illinois at ChicagoOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06068985 | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade(CHERRY-PICK) | active not recruiting | Phase 2 | 63 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06428396 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | active not recruiting | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Aug 28, 2026 | clinicaltrials |
| NCT06475937 | A Study of DM001 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 128 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 28, 2026 | clinicaltrials |
| NCT07462351 | System-integrated Point-of-Care Ultrasound in Breast Cancer Screening(SPRING) | active not recruiting | N/A | 4,800 | Region SkaneOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07782801 | Creation and Implementation a Method for Breast Reconstruction After Radical Surgery Using Decellularized Xenomatrix in Combination With Lymphovenous Anastomosis in Breast Cancer. | active not recruiting | N/A | 60 | National Research Oncology and Transplantology Center, KazakhstanOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01824836 | A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | active not recruiting | N/A | 1,046 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 27, 2026 | clinicaltrials |
| NCT02685332 | Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA | active not recruiting | Phase 1 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04288089 | A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer | active not recruiting | Phase 1 | 31 | Eisai Inc.INDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT06299124 | A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors | active not recruiting | Phase 1 | 40 | Regor Pharmaceuticals Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03995082 | Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey | active not recruiting | N/A | 925 | University of Colorado, DenverOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05306600 | Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System | active not recruiting | — | 882 | Hospital Moinhos de VentoOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05334732 | Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)(SIS) | active not recruiting | N/A | 225 | Virginia Commonwealth UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05767424 | Prospective Observational Study for Breast Microcalcifications' Classification With Artificial Intelligence Techniques | active not recruiting | — | 1,426 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05942105 | Different Localization Techniques for Non-palpable Breast Lesions Comparison: a Retrospective and Multicentric Clinical Study(Localization01) | active not recruiting | — | 1,064 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06577987 | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | active not recruiting | Phase 1 | 220 | Circle PharmaINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials